



# A Pilot Study of Cardiac MRI in Breast Cancer Survivors After Cardiotoxic Chemotherapy and Three-Dimensional Conformal Radiotherapy

Carmen Bergom<sup>1,2\*</sup>, Jason Rubenstein<sup>3</sup>, J. Frank Wilson<sup>2</sup>, Aimee Welsh<sup>3</sup>, El-Sayed H. Ibrahim<sup>4</sup>, Phillip Prior<sup>2</sup>, Aronne M. Schottstaedt<sup>5</sup>, Daniel Eastwood<sup>6</sup>, Mei-Jie Zhang<sup>6</sup>, Adam Currey<sup>2</sup>, Lindsay Puckett<sup>2</sup>, Jennifer L. Strande<sup>3</sup>, Julie A. Bradley<sup>7</sup> and Julia White<sup>8</sup>

## OPEN ACCESS

### Edited by:

Jaroslav T. Hepel,  
Rhode Island Hospital, United States

### Reviewed by:

Wojciech Mazur,  
Christ Hospital, United States  
Sebastian Kelle,  
Deutsches Herzzentrum Berlin,  
Germany

### \*Correspondence:

Carmen Bergom  
cbergom@wustl.edu

### Specialty section:

This article was submitted to  
Radiation Oncology,  
a section of the journal  
Frontiers in Oncology

**Received:** 22 October 2019

**Accepted:** 02 September 2020

**Published:** 16 October 2020

### Citation:

Bergom C, Rubenstein J, Wilson JF, Welsh A, Ibrahim EH, Prior P, Schottstaedt AM, Eastwood D, Zhang M, Currey A, Puckett L, Strande JL, Bradley JA and White J (2020) A Pilot Study of Cardiac MRI in Breast Cancer Survivors After Cardiotoxic Chemotherapy and Three-Dimensional Conformal Radiotherapy.  
*Front. Oncol.* 10:506739.  
doi: 10.3389/fonc.2020.506739

<sup>1</sup> Department of Radiation Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, United States, <sup>2</sup> Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States, <sup>3</sup> Department of Medicine, Division of Cardiology, Medical College of Wisconsin, Milwaukee, WI, United States, <sup>4</sup> Department of Radiology, Medical College of Wisconsin, Milwaukee, WI, United States, <sup>5</sup> Department of Medicine, Case Western Reserve University, Cleveland, OH, United States, <sup>6</sup> Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, United States, <sup>7</sup> Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, United States, <sup>8</sup> Department of Radiation Oncology, James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States

**Purpose/Objectives:** Node-positive breast cancer patients often receive chemotherapy and regional nodal irradiation. The cardiotoxic effects of these treatments, however, may offset some of the survival benefit. Cardiac magnetic resonance (CMR) is an emerging modality to assess cardiac injury. This is a pilot trial assessing cardiac damage using CMR in patients who received anthracycline-based chemotherapy and three-dimensional conformal radiotherapy (3DCRT) regional nodal irradiation using heart constraints.

**Materials and Methods:** Node-positive breast cancer patients (2000–2008) treated with anthracycline-based chemotherapy and 3DCRT regional nodal irradiation (including the internal mammary chain nodes) with heart ventricular constraints (V25 < 10%) were invited to participate. Cardiac tissues were contoured and analyzed separately for whole heart (pericardium) and for combined ventricles and left atrium (myocardium). CMR obtained ventricular function/dimensions, late gadolinium enhancement (LGE), global longitudinal strain (GLS), and extracellular volume fraction (ECV) as measures of cardiac injury and/or early fibrosis. CMR parameters were correlated with dose-volume constraints using Spearman correlations.

**Results:** Fifteen left-sided and five right-sided patients underwent CMR. Median diagnosis age was 50 (32–77). No patients had baseline cardiac disease before regional nodal irradiation. Median time after 3DCRT was 8.3 years (5.2–14.4). Median left-sided mean heart dose (MHD) was 4.8 Gy (1.1–11.2) and V25 was 5.7% (0–12%). Median left ventricular ejection fraction (LVEF) was 63%. No abnormal LGE was observed.

No correlations were seen between whole heart doses and LVEF, LV mass, GLS, or LV dimensions. Increasing ECV did not correlate with increased heart or ventricular doses. However, correlations between higher LV mass and ventricular mean dose, V10, and V25 were seen.

**Conclusion:** At a median follow-up of 8.3 years, this cohort of node-positive breast cancer patients who received anthracycline-based chemotherapy and regional nodal irradiation had no clinically abnormal CMR findings. However, correlations between ventricular mean dose, V10, and V25 and LV mass were seen. Larger corroborating studies that include advanced techniques for measuring regional heart mechanics are warranted.

**Keywords:** 3D conformal radiation therapy, cardiotoxicity, cardiac MRI, radiation therapy, breast cancer

## INTRODUCTION

The use of regional nodal irradiation (RNI) for node positive breast cancer treatment after breast conserving surgery or mastectomy improves local control and survival (1, 2). However, the disease-specific survival advantage of RNI may be attenuated by higher non-breast cancer mortality (3, 4) secondary to cardiac causes (5–9). Patients with left-sided breast cancer receiving radiation have increased rates of major coronary events (9, 10) and cardiac mortality (7, 11). In addition, cardiac deaths (10, 12) correlate with extrapolated mean heart irradiation dose. There is an estimated approximately 4–16% relative increase in heart disease and/or major coronary events for each 1 Gy in mean heart dose received (9, 10, 13). Patients receiving internal mammary chain (IMC) nodal radiation (14) and patients treated with left-sided breast conserving therapy (15) also demonstrate higher late cardiac morbidity. In addition, many breast cancer patients who receive RNI also receive cardiotoxic anthracyclines as part of their chemotherapy (16). Anthracyclines have been shown to increase risk of systolic dysfunction and congestive heart failure as well as subclinical cardiac changes (17–19). Although this risk does not outweigh the survival benefit of anthracyclines (20), cardiac changes can be seen in survivors as far as 18 years or more from diagnosis (21). The interaction of anthracyclines and radiation on cardiovascular outcomes is not fully understood, but additional cardiac risk factors have been shown to increase the absolute risk of cardiac events after radiation therapy (9).

Many of the studies demonstrating increased levels of cardiac morbidity and mortality in breast cancer patients receiving radiation include mostly patients treated prior to the mid-1980s (4, 5, 8, 11). A number of recent breast cancer radiation techniques result in reduced radiation doses to the heart (22–25). Studies of more recent series of breast cancer patients have demonstrated lower excess cardiac mortality from radiotherapy (4, 5, 7, 26). Advances in radiotherapy such as three-dimensional conformal radiation therapy (3DCRT) have allowed quantification of heart irradiation doses and treatments that deliver lower doses of radiation to the heart. Further exploration is therefore warranted to assess the intuitive notion that modern 3DCRT techniques diminish damage to the heart, reduce adverse cardiac events, and improve overall survival.

Cardiac magnetic resonance imaging (CMR) is a powerful modality that allows for sensitive evaluation of cancer therapy-induced cardiac changes (27, 28). While CMR is not as widely used as echocardiograms, its utility is rapidly growing in cardiac research studies as an attractive modality. CMR is more reproducible than echocardiography (29), and CMR has been shown to be superior to echocardiography to identify cardiotoxicity in cancer survivors (30). Furthermore, CMR is not affected by acoustic window or geometric assumptions, and it is less dependent upon operator skills than echocardiography. CMR is also attractive due to its ability to acquire anatomical, functional, and perfusion information in one scanning period with one modality. CMR's exquisite soft tissue contrast and spatial resolution (1–2 mm) may elucidate otherwise masked differences in cardiac parameters (31).

The purpose of this pilot study is to utilize CMR to examine cardiovascular function in women who received both anthracycline-based chemotherapy and RNI using 3DCRT and the use of heart constraints in treatment planning. This study also aims to explore whether CMR-demonstrated changes in perfusion, cardiac function, or cardiac anatomy correlate with the received radiation doses.

## MATERIALS AND METHODS

This Institutional Review Board approved trial (NCT02348684) was conducted by screening a Medical College of Wisconsin database from 2000 to 2008 for lymph node-positive breast cancer patients treated with post-operative 3DCRT RNI with a pre-determined heart constraint (32). Clinicopathologic data were obtained from patient medical records. All patients received either left- or right-sided breast or chest wall irradiation, along with irradiation to the undissected axillary, supraclavicular, and IMC lymph nodes to doses of 45–50 Gy in 1.8–2 Gy fractions. The institutional cardiac dose constraints utilized during this time period required that less than 6% (ideal) and less than 10% (acceptable) (32) of the volume of the left ventricle received 25 Gy (V25), based on studies by Gagliardi and Gyenes (33–35). MHD was not constrained. All contours were recreated and/or verified for the study patients for consistency. Heart contours

included (1) the whole heart as defined by pericardium, and (2) the ventricular volume as defined by both ventricles and the left atrium, excluding pericardium (32). Eligibility criteria were prior anthracycline chemotherapy, no cardiac disease (including heart failure, coronary heart disease, significant valvular disease, or cardiac event such as myocardial infarction) pre-breast cancer diagnosis, and no recurrent breast cancer. Patients unable to tolerate an MRI with contrast were excluded, as well as patients with active atrial fibrillation due to suboptimal CMR images in the setting of this arrhythmia. Eligible women were invited via letter to enroll in this IRB-approved trial. Fifteen left-sided patients and five right-sided patients were enrolled, for a total of twenty patients. CMR parameters evaluated included the following indicators of left ventricular (LV) and right ventricular (RV) function: ejection fraction (EF) and left ventricular mass index (LVMI). LV and RV dimensions were also obtained: LV end-diastolic volume index (LVEDVI), LV end-systolic volume index (LVESVI), RV end-diastolic volume index (RVEDVI), and RV end-systolic volume index (RVESVI). In addition, late gadolinium enhancement (LGE) and total LV myocardial extracellular volume (ECV) fraction were obtained as measures of cardiac scar and/or early cardiac fibrosis (36, 37). The LV was divided into three zones (basal, mid, and apical), and the short axis slices were set up visually to represent these areas. Planned analysis included correlation of CMR parameters with cardiac dose-volume constraints using Spearman correlations.

CMRs were obtained on a Verio 3T MRI scanner (Siemens Healthineers, Erlangen, Germany) with patients imaged in the supine position using commercially available RF transmitter/receiver coils. Geometric assessment of the LV was performed without contrast using a steady-state free precession (SSFP) cine sequence. Imaging parameters were: repetition time (TR) = 56.52 ms, echo time (TE) = 1.36 ms, asymmetric echo with factor 0.41, flip angle (FA) = 42°, field of view (FOV) = 252 mm<sup>2</sup> × 300 mm<sup>2</sup>, matrix of 162 × 192 (in-plane pixel dimensions of 1.56 mm × 1.56 mm), slice thickness = 10 mm, receiver bandwidth (BW) = 1,240 Hz/px, parallel imaging using GRAPPA reconstruction (*R* = 2), and 25 cardiac phases. Gadolinium contrast agent (gadopentetate dimeglumine, *Magnevist*, Bayer Healthcare, Berlin, Germany) was administered at a rate of 0.2 mmol/kg and maximum dose of 20 mmol via peripheral IV. After a 10-min delay, LGE images were obtained for myocardial fibrosis assessment using a T1-weighted, segmented inversion-recovery (IR), fast gradient-echo (GRE) pulse sequence. Imaging parameters were: TR = 750 ms, TE = 1.94 ms, FA = 20°, FOV 340 mm<sup>2</sup> × 265 mm<sup>2</sup>, matrix of 256 × 160, slice thickness = 10 mm, BW = 300 Hz/px, and no acceleration. Coverage of the entire LV was achieved by acquiring 6–8 short-axis (SAX) slices with 10-mm slice spacing, along with long axis images for cross validation. The same heart coverage with identical slice prescriptions were used for both cine and LGE imaging. Qualified cardiac MRI physicians (JR and AW) blinded to the patient identifying information, including dosimetric parameters and side of breast cancer, interpreted the CMR images.

Semi-automated quantification of LV volumes and myocardial mass was performed using CVI42 5.3.0 (Circle Cardiovascular

Imaging, Calgary, Canada). Manual identification of the slice range to be segmented and the mitral valve annulus were performed. Optional corrections comprised manual contouring of epicardial or endocardial surfaces to restrict region-growth and adjusting blood sensitivity. LV volumes were quantified as the sum of short axis chamber volumes (2D area × slice thickness) measured during end-diastole (end diastolic volume, EDV) and end-systole (end systolic volume, ESV). EF was calculated as 100 × (EDV-ESV)/EDV. LV mass was calculated as the product of myocardial volume and specific gravity ([Epicardial EDV-Endocardial EDV] × 1.05). Global longitudinal strain (GLS) was calculated from short and long axis SSFP cine sequences utilizing the Tissue Tracking module of CVI42 5.3.0 (Circle Cardiovascular Imaging, Calgary, Canada).

Contrast-enhanced CMR images were analyzed to determine the amount of LGE versus normal LV myocardial volumes. Any hyperenhanced areas of LGE were manually planimetrically by visual inspection in each SAX slice, including only regions that were fully enhanced and approximately ≥6 standard deviations (SD) above the mean signal of normal myocardium. Identical slices during cine imaging were compared to identify extent of blood pool and epicardial fat. Global ECV was obtained using the 3-3-5 MOLLI MyoMaps motion-corrected T1 map sequence (Siemens Healthineers, Erlangen, Germany) pre-contrast and 15 min post-contrast injection, and corrected with hematocrit obtained on the day of the CMR. Statistical analyses were performed using Graphpad Prism Version 7.0 (GraphPad Software, La Jolla, CA, United States) and SAS version 9.3 (SAS institute, Cary, NC, United States). Spearman's correlations were calculated to determine correlation between heart dose and CMR parameters. Wilcoxon's rank sum tests were used to compare CMR values in left- versus right-sided patients. *P* < 0.05 was considered significant.

## RESULTS

Fifteen left-sided and five right-sided patients were enrolled in this study after obtaining informed consent, and the patients subsequently underwent CMR. The median age of the patients at diagnosis was 50 years (range 32–77). The median age at CMR was 60 years (range 40–83). The median time after 3DCRT was 8.3 years (range 5.7–14.4, **Table 1**). The presence of cardiac risk factors at the time of CMR is shown in **Table 1**. Patient characteristics were similar between groups (**Table 1**). All patients received doxorubicin or epirubicin as part of their chemotherapy. Fifteen patients received doxorubicin and cyclophosphamide, with thirteen patients receiving four cycles, one patient receiving three cycles, and one patient receiving two cycles. Three patients received six cycles of docetaxel, doxorubicin, and cyclophosphamide and two patients received docetaxel, epirubicin, and cyclophosphamide. Two patients also received trastuzumab (one left-sided patient and one right-sided patient) in addition to chemotherapy. Four patients had a ten pack-year or greater smoking history (three left-sided and one right-sided patient). Six patients had hypertension (five left-sided and one right-sided). Two left-sided patients had type II diabetes

**TABLE 1** | Patient characteristics.

Median (range)	All patients (N = 20)	Left-sided (N = 15)	Right-sided (N = 5)
Age at diagnosis	50 (32–77)	49 (35–77)	52 (32–75)
Age at MRI	59 (40–84)	58 (41–84)	64 (40–80)
Follow-up (years)	8.3 (5.2–14.4)	8.2 (5.7–13.9)	8.5 (5.2–14.4)
Receipt of Trastuzumab	2	1	1
Smoking history $\geq$ 10 pack-year	4	3	1
Cardiovascular disease	0	0	0
Hypertension	6	5	1
Hyperlipidemia	6	6	0
Type II diabetes	2	2	0

Patient characteristics and the presence of cardiovascular risk factors at the time of MRI are shown.

(Table 1). None of the patients had a history of clinical cardiac disease at the time of trial enrollment.

The heart dose-volume values for left- and right-sided patients are summarized in Table 2. Among right-sided patients, the median of the mean heart dose (MHD) was 0.6 Gy (0–1.0 Gy), and there was no volume of the heart receiving 5 Gy. Among

**TABLE 2** | Patient cardiac dose-volume radiation parameters.

	Median	Mean	Range
<b>Left-sided patients</b>			
Mean heart dose	4.8 Gy	5.2 Gy	1.1–11.2 Gy
Max heart dose	51.9 Gy	49.2 Gy	11.4–54.4 Gy
Heart V5	16.4%	22.8%	0.2–63.5%
Heart V10	9.9%	14.5%	0–50.3%
Heart V25	5.7%	5.7%	0–12.4%
Heart V45	1.3%	1.3%	0–4.1%
Mean ventricular dose	5.8 Gy	5.6 Gy	0.2–11.2 Gy
Max ventricular dose	51.2 Gy	47.5 Gy	6.3–52.8 Gy
Ventricular V5	21.5%	28.3%	0–77.0%
Ventricular V10	12.1%	16.7%	0–55.1%
Ventricular V25	5.2%	5.9%	0–15.4%
Ventricular V45	0.7%	1.2%	0–3.5%
<b>Right-sided patients</b>			
Mean heart dose	0.6 Gy	0.6 Gy	0–0.1 Gy
Max heart dose	3.8 Gy	3.9 Gy	0–6.4 Gy
Heart V5	0 Gy	0 Gy	0 Gy
Heart V10	0 Gy	0 Gy	0 Gy
Heart V25	0 Gy	0 Gy	0 Gy
Heart V45	0 Gy	0 Gy	0 Gy
Mean ventricular dose	0.4 Gy	0.4 Gy	0–0.8 Gy
Max ventricular dose	2.4 Gy	2.0 Gy	0.2–3.3 Gy
Ventricular V5	0 Gy	0 Gy	0 Gy
Ventricular V10	0 Gy	0 Gy	0 Gy
Ventricular V25	0 Gy	0 Gy	0 Gy
Ventricular V45	0 Gy	0 Gy	0 Gy

Abbreviations: V5, volume of the heart receiving 5 Gy; V10, volume of the heart receiving 10 Gy; V25, volume of the heart receiving 25 Gy; V45, volume of the heart receiving 45 Gy.

left-sided patients, the median MHD was 4.8 Gy (1.0–11.2 Gy) and median heart V25 was 5.7% (0–12.4%); the maximum heart doses ranged from 11–54 Gy (Table 2). For left-sided patients, the median mean ventricular dose was 5.8 Gy (0.2–11.2 Gy) and median ventricular V25 was 5.2% (0–15.4%, Table 2). A summary of CMR values is provided in Table 3. Representative four-chamber inversion recovery delayed enhancement images from three separate patients, without evidence of fibrosis, are shown in Figure 1. The median LVEF was 63%. Pericardial thickness was normal in all patients (<4 mm), and no pericardial abnormalities were found. No first-pass perfusion abnormalities were seen. No late gadolinium enhancement was seen. Two patients had valvular abnormalities found on CMR (a left-sided patient with mild aortic regurgitation and a right-sided patient with mild mitral regurgitation).

Established abnormal values for ECV have not been universally agreed-upon (36, 38–40); however, some studies find that total LV myocardial ECV values correlated with higher likelihood of cardiac events and certain cardiac conditions (36, 40) and that ECV values correlated with myocardial fibrosis seen on biopsy (36). While some patients had total myocardial ECV values about 30%, these values were not higher in patients with left-sided tumors (Table 3), and higher ECV values did not correlate with increased heart (Table 4) or ventricular doses (Table 5). Most of the patients in this cohort had lower absolute GLS values than previously reported normal values (41), with 16/20 patients with lower absolute strain values (Table 3 and Supplementary Material). However, GLS did not correlate with doses of radiation received by the heart or ventricles (Tables 4 and 5). It is unclear whether these patients had lower absolute strain values due to anthracycline exposure or other cardiac risk factors.

LVM (or indexed LVM, LVMI) has been shown to be an independent risk factor for prediction of cardiovascular events (42). However, in this cohort, no abnormally elevated values were seen for LVMI or LV dimensions (Table 3). No abnormal CMR values were seen in the two patients who received trastuzumab. No correlations were seen between the MHD and max heart dose, heart V5, heart V10, heart V25, or the CMR parameters of LVEF, LVMI, or LV dimensions (Table 4). However, there were significant correlations between higher LVMI and the mean ventricular dose ( $r = 0.398$ ,  $P = 0.012$ ), the ventricular V10 ( $r = 0.386$ ,  $P = 0.027$ ), and the ventricular V25 ( $r = 0.425$ ,  $P = 0.016$ , Table 5). Examination of correlations between basal, mid, and apical ECV values and heart or ventricular radiation doses also did not show any significant positive correlations (not shown). No correlations between increased total myocardial ECV measurements and higher heart doses (Table 4) or higher ventricular doses (Table 5) were seen.


## DISCUSSION

A better understanding of the correlation between radiation doses to the heart and subclinical cardiac changes in breast cancer patients in modern series will be helpful to improve the therapeutic ratio of radiation therapy (43). This pilot study examined whether CMR could detect significant subclinical

**TABLE 3** | Cardiac MRI values of patients.

Median (range)	Normal range	All patients (N = 20)	Left-sided (N = 15)	Right-sided (N = 5)	P value (left vs. right)
LVEF	52–72%	63% (52–77%)	64% (52–77%)	61% (56–75%)	0.919
LVEDVI (ml/m <sup>2</sup> )	56–95	63 (46–83)	61 (46–74)	66% (56–83)	0.219
LVESVI (ml/m <sup>2</sup> )	14–34	23 (13–32)	22 (13–32)	26 (14–31)	0.500
LVMI (g/m <sup>2</sup> )	41–81	46 (32–56)	48 (32–56)	40 (38–50)	0.186
GLS	–22.1% to –15.9%	–14.6% (–17.8% to –11.1%)	–14.4% (–16.5% to –11.1%)	–15.6% (–17.8% to –12.9%)	0.161
ECV (total)	–	27% (23–34%)	27% (23–31%)	34% (24–34%)	0.119

Abbreviations: LVEF, left ventricular ejection fraction; LVEDVI, left ventricular end-diastolic volume index; LVESVI, left ventricular end-systolic volume index; LVMI, left ventricular mass index; GLS, global longitudinal strain; ECV, extracellular volume fraction.



**FIGURE 1** | Example CMR Images and Location of Apex, Mid, and Base of Ventricles. **(A–C)** Representative four-chamber inversion recovery delayed enhancement images from three separate patients, without evidence of fibrosis. **(D)** A 4-channel steady-state free precession cine image demonstrating the usual position of the three short axis images that measure ECV for base (1), mid (2), and apex (3) of the left ventricle.

cardiac changes in women who received 3D conformal RNI (planned with heart constraints) and anthracyclines for node-positive breast cancer. With a median follow-up of 8.3 years in this cohort, CMR values were largely within normal limits. However, while the LVMI values were within normal limits (Table 3), there were significant positive correlations between LVMI and the ventricular mean dose, V10, and V25 (Table 5). In addition, increased total heart or ventricular doses were not statistically correlated with increased ECV values, a measure of extracellular volume that is increased in the setting of myocardial injury and an indicator of interstitial fibrosis (37). Correlations of unknown significance were seen between total LV ECV and maximum heart doses, as well as mid-LV ECV and ventricular doses, where lower ECV values correlated with higher radiation doses (Tables 4 and 5). It should be noted that the changes in LVMI without a corresponding change in ECV may be due to increased cardiomyocyte size causing hypertrophy, without or before reactive or replacement fibrosis, as has been seen post-radiation in some patients and preclinical models (44, 45). Total heart or ventricular radiation doses did not correlate with GLS values (Tables 4 and 5).

Radiation-induced cardiac events most commonly include pericarditis, myocardial fibrosis/scar, coronary artery disease, and valvular disease (19, 46). These deficits may be, at least in part, mediated by damage to the microvasculature, causing decreased coronary blood flow and resulting in diastolic dysfunction. This theory is supported by the fact that well-differentiated myocytes are relatively radioresistant. Anthracyclines, in contrast, are directly toxic to myocytes and thus are thought to cause cardiotoxicity possibly through a separate mechanism, which can potentiate the effects of radiation. Macrovascular injury may also contribute, as radiation promotes inflammation and oxidative damage—accelerating atherosclerosis (47). While anthracyclines significantly improve survival in breast cancer patients, notable cardiotoxic side effects can occur (17, 18, 48–50), which increase markedly with increasing dose (19). In this study, we specifically chose to examine potential radiation-induced changes to the heart in patients who not only received regional nodal irradiation, but also received anthracycline-based chemotherapy. In addition, two patients received trastuzumab, which can also cause cardiac injury (51). We saw no clinically abnormal CMR values in these patients, except GLS values (Table 3), which did not

**TABLE 4 |** Correlation between CMR and cardiac radiation dose parameters in all patients, using whole heart dose-volume values.

Spearman correlation (P value)	Mean heart dose	Max heart dose	Heart V5	Heart V10	Heart V25
LVEF	0.044 (0.853)	0.020 (0.932)	0.108 (0.651)	0.105 (0.660)	0.082 (0.732)
LVEDVI	-0.091 (0.710)	-0.218 (0.371)	-0.198 (0.415)	-0.182 (0.455)	-0.013 (0.957)
LVESVI	0.033 (0.892)	-0.131 (0.594)	-0.165 (0.501)	-0.142 (0.563)	-0.004 (0.988)
LVMI	0.389 (0.099)	0.240 (0.323)	0.366 (0.122)	0.386 (0.103)	0.425 (0.070)
GLS	0.275 (0.241)	0.233 (0.324)	0.333 (0.152)	0.277 (0.238)	0.146 (0.540)
ECV (Total)	-0.359 (0.200)	<b>-0.467</b> <b>(0.038)</b>	-0.388 (0.091)	-0.423 (0.063)	-0.422 (0.064)

R-values and P-values are shown. Abbreviations: LVEF, left ventricular ejection fraction; LVEDVI, left ventricular end-diastolic volume index; LVESVI, left ventricular end-systolic volume index; LVMI, left ventricular mass index; GLS, global longitudinal strain; ECV, extracellular volume fraction. Bolded values indicate  $P < 0.05$ .

**TABLE 5 |** Correlation between CMR and cardiac radiation dose parameters in all patients, using ventricular dose-volume values.

Spearman correlation (P value)	Mean ventricular dose	Max ventricular dose	Ventricular V5	Ventricular V10	Ventricular V25
LVEF	-0.044 (0.429)	-0.020 (0.324)	0.108 (0.744)	0.105 (0.739)	0.082 (0.911)
LVEDVI	-0.091 (0.994)	-0.218 (0.353)	-0.198 (0.416)	-0.182 (0.613)	0.013 (0.893)
LVESVI	0.033 (0.596)	-0.131 (0.895)	-0.165 (0.501)	-0.142 (0.621)	-0.004 (0.750)
LVMI	<b>0.398</b> <b>(0.012)</b>	0.240 (0.215)	0.366 (0.087)	<b>0.386</b> <b>(0.027)</b>	<b>0.425</b> <b>(0.016)</b>
GLS	0.237 (0.314)	0.222 (0.348)	0.370 (0.108)	0.300 (0.199)	0.126 (0.596)
ECV (total)	-0.411 (0.072)	<b>-0.454</b> <b>(0.045)</b>	-0.379 (0.100)	-0.418 (0.067)	<b>-0.449</b> <b>(0.047)</b>

R-values and P-values are shown. Abbreviations: LVEF, left ventricular ejection fraction; LVEDVI, left ventricular end-diastolic volume index; LVESVI, left ventricular end-systolic volume index; LVMI, left ventricular mass index; GLS, global longitudinal strain; ECV, extracellular volume fraction. Bolded values indicate  $P < 0.05$ .

correlate with radiation doses (Table 4 and 5). However, the reproducibility of feature tracking can also be variable (52, 53). In addition, feature tracking is not as robust or sensitive as other standard strain measuring techniques, such as tagging, strain-encoding [SENC or fast-SENC (fSENC)] (54–59), or displacement-encoding with stimulated echoes (DENSE) (60). Future studies examining strain using CMR would ideally make use of these more advanced techniques. Especially relevant, recent studies illustrated the capabilities of fSENC for robust and detailed analysis of cardiac function and myocardial contractility pattern as fast as one slice per heartbeat. Such an approach would allow for evaluating cardiac function based on whole-heart strain

analysis in a few seconds without the need for breath-holding or a contrast agent, which is of particular importance in cancer patients who may have difficulties with longer exams (56–59).

Previous studies have found trastuzumab to be cardiotoxic with 5% prevalence of cardiomyopathy when used as monotherapy and 10–15% prevalence when used with anthracyclines (51, 61). Despite receiving both radiation to the heart and cardiotoxic systemic therapy, our cohort of patients did not demonstrate significant abnormal CMR values for LVEF, LVEDVI, LVESVI, LVMI, or ECV. All patients in this study received IMC radiation as part of their RNI. Due to the proximity of IMC nodes to the heart, IMC irradiation can result in higher heart radiation exposure than radiation treatments omitting these regional lymph nodes. IMC nodal treatment has been controversial in practice (62, 63), but the recent MA.20 (64) and EORTC 22922 (65) studies demonstrated benefits of RNI that included treatment of the IMC nodes. Thus, rates of IMC nodal irradiation are likely to increase in the future.

To date nearly all studies evaluating outcomes by SPECT or other measures of cardiac injury have done so in breast cancer patients who did not have their radiation treatments planned with intent to treat IMC and with a heart constraint in place for dosimetric planning. Over the time period the patients in our study were treated, the heart constraint used for left-sided patients at our institution was ventricular V25 < 10% (32). This constraint results in higher MHD than currently accepted in clinical practice. In addition, the whole heart, including the pericardium and the ventricular tissue, were re-contoured on the radiation planning CT to determine received doses for the purposes of this study. In this cohort of patients receiving CMR with a ventricular dose constraint (but without a mean heart dose constraint), the mean heart doses were >5 Gy in 7/15 (47%) left-sided patients and >4 Gy in 10/15 (67%) left-sided patients, with mean heart doses >7.5 Gy in 3/15 (20%) left-sided patients. In right-sided patients, all had mean heart doses less than 0.7 Gy (Table 2). Even with left-sided patients receiving higher mean heart doses than recommended in current practice (mean heart doses <4 Gy when possible), at a median of over 8 years of follow-up, no perfusion defects or significant cardiac abnormalities were seen.

Perfusion changes have been detected in patients who recently received left-sided radiation therapy by using SPECT imaging, with changes correlating to the radiation treatment fields and with the percent of heart in the radiation fields (66–69). There is less data on long-term SPECT changes, although in one study a proportion of patients at 3 and 6 years had perfusion defects after radiation treatments in which the heart was not excluded from the treatment fields (70). Two prospective studies that used cardiac sparing techniques and excluded the entire heart from the radiation beams found no myocardial perfusion defects (71, 72). A recent study using echocardiogram with strain to examine cardiac function in breast cancer patients receiving contemporary radiation and cardiotoxicity systemic therapy did not reveal differences in strain post-radiation, although patients were examined only at 6 months after radiation (73). In this study, CMR was

chosen for its potential to acquire anatomical, functional and perfusion information in one single scanning period, and for its increased spatial resolution (1–2 mm for CMR compared to 1.5 cm for SPECT). Our results are comparable to another study that used CMR to examine breast cancer patients treated with 3DCRT or IMRT up to 24 weeks of treatment. In that study, transient EF decreases were seen at 6 months on MRI, but this resolved by 24 months, and values for most parameters examined were in the normal range at 24 months, without the presence of wall motion abnormalities or late gadolinium enhancement (74).

In this pilot study, we examined women with long-term follow-up after completion of RNI and cardiotoxic chemotherapy using CMR, which can detect functional abnormalities and provide excellent spatial resolution. Taken together, our CMR data suggests that in this cohort there is no significant cardiac injury from receiving both RNI and cardiotoxic chemotherapy, despite relatively high mean heart doses received by a significant proportion of left-sided patients. It is important to note that patients included in this trial had no clinical evidence of cardiac disease at the time of treatment or prior to their study participation. Prior studies have demonstrated that cardiac events are more frequent after radiation in patients with baseline heart disease, thus these results are likely not applicable to this group (9).

In this study, positive correlations were found between ventricular dose volume parameters and LVMI. However, there was no evidence of increased ECV with increasing heart or ventricular radiation doses. It may be that even more refined regional cardiac analysis is necessary to study radiation-induced cardiac changes, as correlations may not be as evident when whole heart or ventricular doses are compared to global heart function. Indeed, the use of standardized cardiac heart substructure contours may allow more refined analysis of risk of cardiac disease based upon dose localization within the heart (75). For future studies, including advanced CMR techniques for studying regional heart mechanics (76) [e.g., MRI tagging (77), fSENC (54–59), or DENSE (60)] could reveal important information about myocardial regional contractility patterns that are expected to be affected at earlier timepoints after radiation, before reduction of global heart function and heart failure development. For global LV geometric measurements (LVEDV, LVEDVI, LVESV, LVESVI, LVEF and LVMI), only short-axis data was used. The inclusion of long-axis data and combining geometric data from multiple orientations in future studies would be expected to reduce the inherent geometric errors, potentially revealing significant changes that could have been masked in the current analysis.

Strengths of this study include the long median follow-up in patients who received anthracyclines and regional nodal irradiation, as well as receipt of radiation treatment using 3DCRT which allowed determination of cardiac and ventricular doses. However, this pilot study is limited by the small cohort of patients, as well as the lack of details regarding exercise capacity, detailed clinical symptoms, or cardiac biomarkers, although hypothesis-generating findings

are seen with respect to ventricular radiation doses and LVMI. The CMR values were largely within normal limits despite a median MHD of >4 Gy for breast cancer patients enrolled in this study. This finding may reflect that in this population of patients without clinical cardiac disease there is a higher threshold for cardiac injury. Alternatively, this finding could mean that radiation therapy planned with cardiac constraints successfully limited partial heart injury, unlike prior studies evaluating cardiac injury from radiation delivered without constraints. It could also be that differences were present, but they were masked by the inherent uncertainties of in the estimation methods used. There is also the possibility of bias, as these 20 women self-selected from a cohort of women invited by letter to return for cardiac MRI. In addition, significant differences could have been present, but were masked by the inherent uncertainties in the estimation methods to obtain CMR values. For future studies, additional more sensitive analyses using CMR with multiple geometric views, regional strain analysis, and feature tracking may improve sensitivity to detect subclinical radiation changes. In addition, baseline CMR data was not available for this cohort of patients. However, the correlations seen between ventricular dose volume parameters and LVMI values are hypothesis-generating. Larger corroborating studies are warranted to further examine the utility of CMR in detection of therapy-induced heart disease in node positive breast cancer patients who receive both cardiotoxic chemotherapy and radiation.

## DATA AVAILABILITY STATEMENT

All datasets generated for this study are included in the article/**Supplementary Material**.

## ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Medical College of Wisconsin Institutional Review Board. The patients/participants provided their written informed consent to participate in this study.

## AUTHOR CONTRIBUTIONS

JW, JAB, JR, and CB contributed to the conception and design of the study. CB, PP, JB, AW, AC, and JR collected the data. JR, CB, M-JZ, and DE performed statistical analyses. JR, AW, JLS, AC, and E-SHI interpreted the data. AMS and CB wrote initial drafts of the manuscript. JAB, JW, JFW, and LP wrote and edited sections of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.

## FUNDING

CB has received funding from the NIH (1R01HL147884-01 and U01AI133594-01), the Radiation Oncology Institute, the

Susan G. Komen Foundation (CCR17483233), The Mary Kay Foundation (Grant 017-29), the Cardiovascular Center and Cancer Center at the Medical College of Wisconsin (CB), and an Institutional Research Grant 86-004-26 from the American Cancer Society.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fonc.2020.506739/full#supplementary-material>

## REFERENCES

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. *Lancet*. (2011) 378:1707–16. doi: 10.1016/S0140-6736(11)61629-2
2. EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. *Lancet*. (2014) 383:2127–35. doi: 10.1016/S0140-6736(14)60488-8
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. *Lancet*. (2000) 355:1757–70. doi: 10.1016/S0140-6736(00)02263-7
4. Hoening MJ, Aleman BMP, van Rosmalen AJM, Kuenen MA, Klijn JGM, van Leeuwen FE. Cause-specific mortality in long-term survivors of breast cancer: a 25-year follow-up study. *Int J Radiat Oncol*. (2006) 64:1081–91. doi: 10.1016/j.ijrobp.2005.10.022
5. Cuzick J, Stewart H, Rutqvist L, Houghton J, Edwards R, Redmond C, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. *J Clin Oncol*. (1994) 12:447–53. doi: 10.1200/jco.1994.12.3.447
6. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. *Lancet*. (2005) 366:2087–106. doi: 10.1016/S0140-6736(05)67887-7
7. Henson KE, McGale P, Taylor C, Darby SC. Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. *Br J Cancer*. (2013) 108:179–82. doi: 10.1038/bjc.2012.575
8. Bouillon K, Haddy N, Delaloue S, Garbay J-R, Garsi J-P, Brindel P, et al. Long-term cardiovascular mortality after radiotherapy for breast cancer. *J Am Coll Cardiol*. (2011) 57:445–52. doi: 10.1016/j.jacc.2010.08.638
9. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Engl J Med*. (2013) 368:987–98. doi: 10.1056/NEJMoa1209825
10. Taylor C, Correa C, Duane FK, Aznar MC, Anderson SJ, Bergh J, et al. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. *J Clin Oncol*. (2017) 35:1641–9. doi: 10.1200/JCO.2016.72.0722
11. Rutqvist LE, Johansson H. Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish cancer registry. *Br J Cancer*. (1990) 61:866–8. doi: 10.1038/bjc.1990.193
12. Gyenes G, Rutqvist LE, Liedberg A, Fornander T. Long-term cardiac morbidity and mortality in a randomized trial of pre- and postoperative radiation therapy versus surgery alone in primary breast cancer. *Radiation Oncol*. (1998) 48:185–90.
13. van den Bogaard VAB, Ta BDP, van der Schaaf A, Bouma AB, Middag AMH, Bantema-Joppe EJ, et al. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures. *J Clin Oncol*. (2017) 35:1171–8. doi: 10.1200/JCO.2016.69.8480
14. Hoening MJ, Botma A, Aleman BMP, Baaijens MHA, Bartelink H, Klijn JGM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. *J Natl Cancer Inst*. (2007) 99:365–75. doi: 10.1093/jnci/djk064
15. Harris EER, Correa C, Hwang W-T, Liao J, Litt HI, Ferrari VA, et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. *J Clin Oncol*. (2006) 24:4100–6. doi: 10.1200/JCO.2005.05.1037
16. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet*. (2005) 365:1687–717. doi: 10.1016/S0140-6736(05)66544-0
17. Drafts BC, Twomley KM, D'Agostino R, Lawrence J, Avis N, Ellis LR, et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. *JACC Cardiovasc Imaging*. (2013) 6:877–85. doi: 10.1016/j.jcmg.2012.11.017
18. Stoodley PW, Richards DAB, Boyd A, Hui R, Harnett PR, Meikle SR, et al. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months. *Eur J Cancer*. (2013) 49:3396–403. doi:10.1016/j.ejca.2013.06.046
19. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. *J Am Coll Cardiol*. (2009) 53:2231–47. doi: 10.1016/j.jacc.2009.02.050
20. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. *J Clin Oncol*. (2005) 23:8597–605. doi: 10.1200/JCO.2005.02.5841
21. de Azambuja E, Ameje L, Diaz M, Vandenbossche S, Aftimos P, Bejarano Hernández S, et al. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. *Eur J Cancer*. (2015) 51:2517–24. doi: 10.1016/j.ejca.2015.08.011
22. Bergom C, Currey A, Desai N, Tai A, Strauss JB. Deep inspiration breath hold: techniques and advantages for cardiac sparing during breast cancer irradiation. *Front Oncol*. (2018) 8:87. doi: 10.3389/fonc.2018.00087
23. Bradley JA, Dagan R, Ho MW, Rutenberg M, Morris CG, Li Z, et al. Initial report of a prospective dosimetric and clinical feasibility trial demonstrates the potential of protons to increase the therapeutic ratio in breast cancer compared with photons. *Int J Radiat Oncol Biol Phys*. (2016) 95:411–21. doi: 10.1016/j.ijrobp.2015.09.018
24. Bergom C, Kelly T, Morrow N, Wilson JF, Walker A, Xiang Q, et al. Prone whole-breast irradiation using three-dimensional conformal radiotherapy in women undergoing breast conservation for early disease yields high rates of excellent to good cosmetic outcomes in patients with large and/or pendulous breasts. *Int J Radiat Oncol Biol Phys*. (2012) 83:821–8. doi: 10.1016/j.ijrobp.2011.08.020
25. Bradley JA, Mendenhall NP. Novel radiotherapy techniques for breast cancer. *Annu Rev Med*. (2018) 69:277–88. doi: 10.1146/annurev-med-042716-103422
26. Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. *Lancet Oncol*. (2005) 6:557–65. doi: 10.1016/S1470-2045(05)70251-5
27. Jordan JH, Todd RM, Vasu S, Hundley WG. Cardiovascular magnetic resonance in the oncology patient. *JACC Cardiovasc Imaging*. (2018) 11:1150–72. doi: 10.1016/j.jcmg.2018.06.004
28. Plana JC, Thavendiranathan P, Bucchiarelli-Ducci C, Lancellotti P. Multimodality imaging in the assessment of cardiovascular toxicity in the cancer patient. *JACC Cardiovasc Imaging*. (2018) 11:1173–86. doi: 10.1016/j.jcmg.2018.06.003
29. Marwick Thomas H, Neubauer S, Petersen SE. Use of cardiac magnetic resonance and echocardiography in population-based studies. *Circ Cardiovasc Imaging*. (2013) 6:590–6. doi: 10.1161/CIRCIMAGING.113.000498
30. Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, et al. Screening adult survivors of childhood cancer for cardiomyopathy:



- comparison of echocardiography and cardiac magnetic resonance imaging. *J Clin Oncol.* (2012) 30:2876–84. doi: 10.1200/JCO.2011.40.3584
31. Zellars R, Bravo PE, Tryggestad E, Hopfer K, Myers L, Tahari A, et al. Analysis of cardiac perfusion changes after whole-Breast/Chest wall radiation therapy with or without active breathing coordinator: results of a randomized phase 3 trial. *Int J Radiat Oncol Biol Phys.* (2014) 88:778–85. doi: 10.1016/j.ijrobp.2013.12.035
  32. Prior P, Sparks I, Wilson JF, Bovi J, Currey A, Bradley J, et al. Use of three dimensional conformal radiation therapy for node positive breast cancer does not result in excess lung and heart irradiation. *Int J Med Phys Clin Eng Radiat Oncol.* (2017) 06:1. doi: 10.4236/ijmpcero.2017.61001
  33. Gyenes G, Gagliardi G, Lax I, Fornander T, Rutqvist LE. Evaluation of irradiated heart volumes in stage I breast cancer patients treated with postoperative adjuvant radiotherapy. *J Clin Oncol.* (1997) 15:1348–53. doi: 10.1200/JCO.1997.15.4.1348
  34. Gagliardi G, Lax I, Ottolenghi A, Rutqvist LE. Long-term cardiac mortality after radiotherapy of breast cancer—application of the relative seriality model. *Br J Radiol.* (1996) 69:839–46. doi: 10.1259/0007-1285-69-825-839
  35. doi: 10.1016/s0167-8140(97)00167-9 Gagliardi G, Lax I, Söderström S, Gyenes G, Rutqvist LE. Prediction of excess risk of long-term cardiac mortality after radiotherapy of stage I breast cancer. *Radiother Oncol.* (1998) 46:63–71.
  36. Kammerlander AA, Marzluf BA, Zotter-Tufaro C, Aschauer S, Duca F, Bachmann A, et al. T1 mapping by CMR imaging: from histological validation to clinical implication. *JACC Cardiovasc Imaging.* (2016) 9:14–23. doi: 10.1016/j.jcmg.2015.11.002
  37. Scully PR, Bastarrrika G, Moon JC, Treibel TA. Myocardial extracellular volume quantification by cardiovascular magnetic resonance and computed tomography. *Curr Cardiol Rep.* (2018) 20:15. doi: 10.1007/s11886-018-0961-3
  38. Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. *J Cardiovasc Magn Reson.* (2016) 18:89. doi: 10.1186/s12968-016-0308-4
  39. Radunski UK, Lund GK, Stehning C, Schnackenburg B, Bohnen S, Adam G, et al. CMR in patients with severe myocarditis: diagnostic value of quantitative tissue markers including extracellular volume imaging. *JACC Cardiovasc Imaging.* (2014) 7:667–75. doi: 10.1016/j.jcmg.2014.02.005
  40. Sado DM, Flett AS, Banyersad SM, White SK, Maestrini V, Quarta G, et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. *Heart.* (2012) 98:1436–41. doi: 10.1136/heartjnl-2012-302346
  41. Yingchoncharoen T, Agarwal S, Popoviæ ZB, Marwick TH. Normal ranges of left ventricular strain: a meta-analysis. *J Am Soc Echocardiogr.* (2013) 26:185–91. doi: 10.1016/j.echo.2012.10.008
  42. Armstrong AC, Gidding S, Gjesdal O, Wu C, Bluemke DA, Lima JAC. LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. *JACC Cardiovasc Imaging.* (2012) 5:837–48. doi: 10.1016/j.jcmg.2012.06.003
  43. Hall WA, Bergom C, Thompson RF, Baschnagel AM, Vijayakumar S, Willers H, et al. Precision oncology and genomically guided radiation therapy: a report from the american society for radiation oncology/american association of physicists in medicine/national cancer institute precision medicine conference. *Int J Radiat Oncol Biol Phys.* (2018) 101:274–84. doi: 10.1016/j.ijrobp.2017.05.044
  44. Sárközy M, Gáspár R, Zvara Á, Kiscsatári L, Varga Z, Kövári B, et al. Selective heart irradiation induces cardiac overexpression of the Pro-hypertrophic miR-212. *Front Oncol.* (2019) 9:598. doi: 10.3389/fonc.2019.00598
  45. Monceau V, Llach A, Azria D, Bridier A, Petit B, Mazevet M, et al. Epac contributes to cardiac hypertrophy and amyloidosis induced by radiotherapy but not fibrosis. *Radiother Oncol.* (2014) 111:63–71. doi: 10.1016/j.radonc.2014.01.025
  46. Yusuf SW, Venkatesulu BP, Mahadevan LS, Krishnan S. Radiation-induced cardiovascular disease: a clinical perspective. *Front Cardiovasc Med.* (2017) 4:66. doi: 10.3389/fcvm.2017.00066
  47. Taylor CW, Nisbet A, McGale P, Goldman U, Darby SC, Hall P, et al. Cardiac doses from Swedish breast cancer radiotherapy since the 1950s. *Radiother Oncol.* (2009) 90:127–35. doi: 10.1016/j.radonc.2008.09.029
  48. Alııcı H, Balakan O, Ercan S, Çakıcı M, Yavuz F, Davutođlu V. Evaluation of early subclinical cardiotoxicity of chemotherapy in breast cancer. *Anatol J Cardiol.* (2015) 15:56–60. doi: 10.5152/akd.2014.5185
  49. Vejpongsa P, Yeh ETH. Topoisomerase 2 $\beta$ : a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. *Clin Pharmacol Ther.* (2014) 95:45–52. doi: 10.1038/clpt.2013.201
  50. Yeh ETH, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. *Circulation.* (2004) 109:3122–31. doi: 10.1161/01.CIR.0000133187.74800.B9
  51. Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. *J Am Coll Cardiol.* (2011) 57:2263–70. doi: 10.1016/j.jacc.2010.11.063
  52. Morton G, Schuster A, Jogiya R, Kutty S, Beerbaum P, Nagel E. Inter-study reproducibility of cardiovascular magnetic resonance myocardial feature tracking. *J Cardiovasc Magn Reson.* (2012) 14:43. doi: 10.1186/1532-429X-14-43
  53. Schuster A, Morton G, Hussain ST, Jogiya R, Kutty S, Asrress KN, et al. The intra-observer reproducibility of cardiovascular magnetic resonance myocardial feature tracking strain assessment is independent of field strength. *Eur J Radiol.* (2013) 82:296–301. doi: 10.1016/j.ejrad.2012.11.012
  54. Osman NF, Sampath S, Atalar E, Prince JL. Imaging longitudinal cardiac strain on short-axis images using strain-encoded MRI. *Magn Reson Med.* (2001) 46:324–34. doi: 10.1002/mrm.1195
  55. Pan L, Stuber M, Kraitchman DL, Fritzsche DL, Gilson WD, Osman NF. Real-time imaging of regional myocardial function using fast-SENCE. *Magn Reson Med.* (2006) 55:386–95. doi: 10.1002/mrm.20770
  56. Korosoglou G, Giusca S, Hofmann NP, Patel AR, Lapinskas T, Pieske B, et al. Strain-encoded magnetic resonance: a method for the assessment of myocardial deformation. *ESC Heart Fail.* (2019) 6:584–602. doi: 10.1002/ehf2.12442
  57. Lapinskas T, Zieschang V, Erley J, Stoiber L, Schnackenburg B, Stehning C, et al. Strain-encoded cardiac magnetic resonance imaging: a new approach for fast estimation of left ventricular function. *BMC Cardiovasc Disord.* (2019) 19:52. doi: 10.1186/s12872-019-1031-5
  58. Giusca S, Korosoglou G, Zieschang V, Stoiber L, Schnackenburg B, Stehning C, et al. Reproducibility study on myocardial strain assessment using fast-SENCE cardiac magnetic resonance imaging. *Sci Rep.* (2018) 8:14100. doi: 10.1038/s41598-018-32226-3
  59. Erley J, Zieschang V, Lapinskas T, Demir A, Wiesemann S, Haas M, et al. A multi-vendor, multi-center study on reproducibility and comparability of fast strain-encoded cardiovascular magnetic resonance imaging. *Int J Cardiovasc Imaging.* (2020) 36:899–911. doi: 10.1007/s10554-020-01775-y
  60. Aletras AH, Ding S, Balaban RS, Wen H. DENSE: displacement encoding with stimulated echoes in cardiac functional MRI. *J Magn Reson.* (1999) 137:247–52. doi: 10.1006/jmre.1998.1676
  61. Lawley C, Wainwright C, Segelov E, Lynch J, Beith J, McCrohon J. Pilot study evaluating the role of cardiac magnetic resonance imaging in monitoring adjuvant trastuzumab therapy for breast cancer. *Asia Pac J Clin Oncol.* (2012) 8:95–100. doi: 10.1111/j.1743-7563.2011.01462.x
  62. Thorsen LB, Offersen BV, Danø H, Berg M, Jensen I, Pedersen AN, et al. DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. *J Clin Oncol.* (2016) 34:314–20. doi: 10.1200/JCO.2015.63.6456
  63. Hennequin C, Bossard N, Servagi-Vernat S, Maingon P, Dubois J-B, Datchary J, et al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. *Int J Radiat Oncol Biol Phys.* (2013) 86:860–6. doi: 10.1016/j.ijrobp.2013.03.021
  64. Whelan TJ, Olivetto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. Regional nodal irradiation in early-stage breast cancer. *N Engl J Med.* (2015) 373:307–16. doi: 10.1056/NEJMoa1415340
  65. Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, et al. Internal mammary and medial supraclavicular

- irradiation in breast cancer. *N Engl J Med.* (2015) 373:317–27. doi: 10.1056/NEJMoa1415369
66. Gyenes G, Fornander T, Carlens P, Glas U, Rutqvist LE. Detection of radiation-induced myocardial damage by technetium-99m sestamibi scintigraphy. *Eur J Nucl Med.* (1997) 24:286–92. doi: 10.1007/s002590050054
  67. Evans ES, Prosnitz RG, Yu X, Zhou S-M, Hollis DR, Wong TZ, et al. Impact of patient-specific factors, irradiated left ventricular volume, and treatment set-up errors on the development of myocardial perfusion defects after radiation therapy for left-sided breast cancer. *Int J Radiat Oncol Biol Phys.* (2006) 66:1125–34. doi: 10.1016/j.ijrobp.2006.06.025
  68. Marks LB, Yu X, Prosnitz RG, Zhou S-M, Hardenbergh PH, Blazing M, et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. *Int J Radiat Oncol Biol Phys.* (2005) 63:214–23. doi: 10.1016/j.ijrobp.2005.01.029
  69. Hardenbergh PH, Munley MT, Bentel GC, Kedem R, Borges-Neto S, Hollis D, et al. Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. *Int J Radiat Oncol Biol Phys.* (2001) 49:1023–8. doi: 10.1016/S0360-3016(00)01531-5
  70. Prosnitz RG, Hubbs JL, Evans ES, Zhou S-M, Yu X, Blazing MA, et al. Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment. *Cancer.* (2007) 110:1840–50. doi: 10.1002/cncr.22965
  71. Zagar TM, Tang X, Jones EL, Matney J, Das S, Green R, et al. Prospective assessment of deep inspiration breath hold to prevent radiation associated cardiac perfusion defects in patients with left-sided breast cancer. *Int J Radiat Oncol Biol Phys.* (2015) 93:E11. doi: 10.1016/j.ijrobp.2015.07.572
  72. Chung E, Corbett JR, Moran JM, Griffith KA, Marsh RB, Feng M, et al. Is there a dose-response relationship for heart disease with low-dose radiation therapy? *Int J Radiat Oncol Biol Phys.* (2013) 85:959–64. doi: 10.1016/j.ijrobp.2012.08.002
  73. Yu AF, Ho AY, Braunstein LZ, Thor ME, Lee Chuy K, Eaton A, et al. Assessment of early radiation-induced changes in left ventricular function by myocardial strain imaging after breast radiation therapy. *J Am Soc Echocardiogr.* (2019) 32:521–8. doi: 10.1016/j.echo.2018.12.009
  74. Heggemann F, Grotz H, Welzel G, Dösch C, Hansmann J, Kraus-Tiefenbacher U, et al. Cardiac function after multimodal breast cancer therapy assessed with functional magnetic resonance imaging and echocardiography imaging. *Int J Radiat Oncol Biol Phys.* (2015) 93:836–44. doi: 10.1016/j.ijrobp.2015.07.2287
  75. Feng M, Moran JM, Koelling T, Chughtai A, Chan JL, Freedman L, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. *Int J Radiat Oncol Biol Phys.* (2011) 79:10–8. doi: 10.1016/j.ijrobp.2009.10.058
  76. Ibrahim E-SH. Myocardial tagging by cardiovascular magnetic resonance: evolution of techniques—pulse sequences, analysis algorithms, and applications. *J Cardiovasc Magn Reson.* (2011) 13:36. doi: 10.1186/1532-429X-13-36
  77. O'Dell WG, Moore CC, Hunter WC, Zerhouni EA, McVeigh ER. Three-dimensional myocardial deformations: calculation with displacement field fitting to tagged MR images. *Radiology.* (1995) 195:829–35. doi: 10.1148/radiology.195.3.7754016

**Conflict of Interest:** JAB has received a travel grant from Ion Beam Applications.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Bergom, Rubenstein, Wilson, Welsh, Ibrahim, Prior, Schottstaedt, Eastwood, Zhang, Currey, Puckett, Strande, Bradley and White. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.